01 3Pantoloc/Controloc
02 5Pantoprazole
03 1Protonix
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 493
2018 Revenue in Millions : 588
Growth (%) : -16
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 413
2019 Revenue in Millions : 503
Growth (%) : -18
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 344
2020 Revenue in Millions : 396
Growth (%) : -6
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 339
2021 Revenue in Millions : 344
Growth (%) : -1
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 322
2022 Revenue in Millions : 339
Growth (%) : 7
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2014 Revenue in Millions : 7.00%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 709
2015 Revenue in Millions : 943
Growth (%) : -25
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 643
2016 Revenue in Millions : 756
Growth (%) : -15
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 569
2017 Revenue in Millions : 603
Growth (%) : -6%
LOOKING FOR A SUPPLIER?